Description

Hypertension is the most dangerous factor that leads to the occurrence and resulting death of heart disease, cerebrovascular disease and kidney disease. According to the statistics of WHO, by 2030, nearly 23.6 million around the world will die of cardiovascular disease especially heart disease and apoplexy each year.

With the change of life styles brought about by economic development, the incidence of hypertension keeps growing in China. The number of hypertension patients is estimated to be 266 million with one in five adults suffering from it. Cardia-cerebrovascular disease is the leading cause of death in China and 50% of it relate to hypertension. Therefore, the effective control of hypertension and prevention of cardia-cerebrovascular disease has become an important health concern for health care workers and the public. On the other hand, patients need long-term pharmacotherapy for hypertension is a controllable disease.

View Full Report at: http://www.marketresearchreports.biz/analysis/289070

In 1991, olmesartan medoxomil was successfully developed by Sankyo Pharmaceuticals Co., Ltd and was patented in many countries. In Apr. 2002, olmesartan medoxomil was approved by FDA to enter the American market in May. It has now become the best-selling drug in the world after it succeeded in the US market.

Compared with other ARBs, olmesartan medoxomil has distinctive pharmacokinetic properties. It develops fast after entering China with annual sales rising from CNY 4448 in 2010 to CNY 99.07 million and CAGR reaching up to 204.15%. Currently, there are three manufacturers of olmesartan in Chinese market: Shanghai Sankyo Pharmaceuticals Co., Ltd, Shanghai Sine Promod Pharmaceutical Co., Ltd and Beijing Winsunny Pharmaceutical Co., Ltd, among which Shanghai Sankyo Pharmaceuticals Co., Ltd has the biggest market share of 94.45% in 2014 with sales value reaching up to CNY 93.57 million in the same year.

With the increase of the incidence of cardiovascular disease and its number of cases, the market size of olmesartan is estimated to keep expanding in the next few years.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289070

Readers can get at least the following information through this report:

market size of olmesartan in China
major manufacturers of olmesartan in the Chinese market and their market share
retail price of olmesartan in China
market outlook of olmesartan in China

The author suggests the following groups of people purchase this report:

manufacturers of cardiovascular system drugs
investors/ research institutions interested in Chinese medicine market
any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Content

1 Related Concepts of Olmesartan
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Olmesartan in China
2.1 Patent and Approval Status of Olmesartan in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Olmesartan in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz


Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]